AIM ImmunoTech
12 hedge funds and large institutions have $105K invested in AIM ImmunoTech in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 22 closing their positions.
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
63% less funds holding
Funds holding: 32 → 12 (-20)
82% less capital invested
Capital invested by funds: $590K → $105K (-$485K)
91% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Corient Private Wealth
Miami,
Florida
|
+$98.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.9K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$298K |
| 2 |
BlackRock
New York
|
-$85.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$65K |
| 4 |
Renaissance Technologies
New York
|
-$38.9K |
| 5 |
State Street
Boston,
Massachusetts
|
-$21.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JWCA
26
J.W. Cole Advisors
Tampa,
Florida
| – | -$1.83K | -150 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$1.75K | -143 | Closed |
|
|
DBRC
28
D.B. Root & Company
Pittsburgh,
Pennsylvania
| – | -$1.47K | -121 | Closed |
|
|
TCM
29
Traynor Capital Management
Malvern,
Pennsylvania
| – | -$1.44K | -118 | Closed |
|
|
HWM
30
HB Wealth Management
Atlanta,
Georgia
| – | -$1.22K | -100 | Closed |
|
|
TWC
31
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$20 | -2 | Closed |
|
|
HNB
32
Huntington National Bank
Columbus,
Ohio
| – | -$7 | -1 | Closed |
|
33
JP Morgan Chase
New York
| – | -$15 | -1 | Closed |
|
|
MCM
34
MAI Capital Management
Independence,
Ohio
| – | -$4 | – | – |
|
AIM Hedge Fund Activity: Q2 2025 in Review
12 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2025, worth a combined $105K — down 82% from $590K a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AIM and 2 opened new positions — a net loss of 20 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Corient Private Wealth, opening a new position worth an estimated $98.8K. The largest seller was Vanguard Group, exiting entirely with an estimated $298K sold.
- 12 institutional investors held AIM ImmunoTech (AIM) as of Q2 2025, down from 32 in Q1 2025.
- Funds reported $105K of AIM ImmunoTech stock for Q2 2025, down 82% quarter-over-quarter.
- 2 funds opened new AIM ImmunoTech positions in Q2 2025 and 22 closed out, a net change of -20 holders.
- The largest AIM ImmunoTech buyer in Q2 2025 was Corient Private Wealth, an estimated $98.8K added.
- The largest AIM ImmunoTech seller in Q2 2025 was Vanguard Group, an estimated $298K sold.
Based on aggregated 13F filings for Q2 2025.